评论文章：肿瘤患者临床试验期间疑似药物性肝损伤的检测、评估和管理建议

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2024-09-19 DOI:10.1111/apt.18271

Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi, Arie Regev, Melissa Palmer, Don Rockey, Robert Fontana, Paul H. Hayashi, Hans L. Tillmann, Adrian M. Di Bisceglie, James H. Lewis

{"title":"评论文章：肿瘤患者临床试验期间疑似药物性肝损伤的检测、评估和管理建议","authors":"Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi, Arie Regev, Melissa Palmer, Don Rockey, Robert Fontana, Paul H. Hayashi, Hans L. Tillmann, Adrian M. Di Bisceglie, James H. Lewis","doi":"10.1111/apt.18271","DOIUrl":null,"url":null,"abstract":"Drug-induced liver injury (DILI) is a major concern for oncology drugs in clinical practice and under development. Monitoring cancer patients for hepatotoxicity is challenging as these patients may have abnormal liver tests pre-treatment or on-study for many reasons including liver injury due to past oncology treatments, hepatic metastases, medical co-morbidities such as heart failure, and concomitant medications. At present, there are no regulatory guidelines or position papers that systematically address best practices pertaining to DILI detection, assessment and management in oncology patients.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients\",\"authors\":\"Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi, Arie Regev, Melissa Palmer, Don Rockey, Robert Fontana, Paul H. Hayashi, Hans L. Tillmann, Adrian M. Di Bisceglie, James H. Lewis\",\"doi\":\"10.1111/apt.18271\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Drug-induced liver injury (DILI) is a major concern for oncology drugs in clinical practice and under development. Monitoring cancer patients for hepatotoxicity is challenging as these patients may have abnormal liver tests pre-treatment or on-study for many reasons including liver injury due to past oncology treatments, hepatic metastases, medical co-morbidities such as heart failure, and concomitant medications. At present, there are no regulatory guidelines or position papers that systematically address best practices pertaining to DILI detection, assessment and management in oncology patients.\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.18271\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18271","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

药物性肝损伤（DILI）是临床实践中和研发中的肿瘤药物的一个主要问题。对癌症患者进行肝毒性监测具有挑战性，因为这些患者在治疗前或研究过程中可能会出现肝功能检测异常，原因有很多，包括既往肿瘤治疗导致的肝损伤、肝转移、心力衰竭等并发症以及同时服用药物。目前，还没有监管指南或立场文件系统地阐述有关肿瘤患者 DILI 检测、评估和管理的最佳实践。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients

查看原文本刊更多论文

Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients

Drug-induced liver injury (DILI) is a major concern for oncology drugs in clinical practice and under development. Monitoring cancer patients for hepatotoxicity is challenging as these patients may have abnormal liver tests pre-treatment or on-study for many reasons including liver injury due to past oncology treatments, hepatic metastases, medical co-morbidities such as heart failure, and concomitant medications. At present, there are no regulatory guidelines or position papers that systematically address best practices pertaining to DILI detection, assessment and management in oncology patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.